This observational analysis is the first to compare combination therapy of newer generation GLP-1RAs (including dual GLP-1/GIP agonists) and SGLT2is with SGLT2is alone and provides reassurance that the combination is likely more effective for improving cardiorenal and metabolic outcomes in people with T2D. This evidence concerns the gene GIP and type 2 diabetes mellitus.